Astrazeneca Share News (AZN)
AZN Share
AZN Share
AZN Share
AZN Share
AZN
AZN Share
AZN Level 2
AZN Live
AZN Broker
AZN Directors
AZN Financial
AZN
AZN Short
AZN
Last checked at -
Tue, 03rd Mar 2015 07:10
(Alliance News) - AstraZeneca PLC on Thursday said that the EU approved its prescription medicine Truqap, in combination with hormonal therapy Faslodex, for the treatment of a form of breast cancer.
Read more(Alliance News) - AstraZeneca PLC on Tuesday said findings from a breast cancer drug trial showed that Truqap did not meet its primary endpoints.
Read more(Alliance News) - London's FTSE 100 is called to open higher on Tuesday, taking confidence from a decent showing for US equities overnight, with inflation data and central bank decisions the key plot points as the week progresses.
Read more(Sharecast News) - AstraZeneca announced on Tuesday that the phase three 'CAPItello-290' trial for 'Truqap', or capivasertib, in combination with paclitaxel did not achieve its primary endpoints.
Read more(Alliance News) - AstraZeneca PLC on Monday said it secured a new US approval for cancer treatment Imfinzi, also known as durvalumab, hailing an "important new option" for patients.
Read more(Alliance News) - London's FTSE 100 is called to open solidly higher on Monday, recovering some poise after a tricky week, with eyes turning to the Bank of England.
Read moreAstraZeneca PLC - Cambridge, England-based pharmaceutical maker - Reports promising test results for one of its cancer therapies. The Echo phase III trial shows that Calquence, when used in combination with bendamustine and rituximab, demonstrates a clinically meaningful improvement in progression-free survival in patients with untreated mantle cell lymphoma. Compared to standard-of-care chemoimmunotherapy, the combination with Calquence, whose generic name is acalabrutinib, shows a 27% reduced risk of disease progression or death. Mantle cell lymphoma is rare and typically aggressive form of non-Hodgkin lymphoma, Astra explains.
Read more(Sharecast News) - AstraZeneca said its Imfinzi cancer treatment had been approved in the US as treatment for adult patients with primary advanced or recurrent endometrial cancer.
Read more(Alliance News) - AstraZeneca PLC on Wednesday said its Farxiga treatment has been approved in the US to treat some diabetes sufferers.
Read more(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and on Friday:
Read more(Alliance News) - AstraZeneca PLC on Monday celebrated a breakthrough therapy designation for its cancer drug Tagrisso, aimed at treating a form of non-small cell lung cancer.
Read more(Alliance News) - Stocks in London are called to open lower on Monday, setting off the week on the backfoot, with eyes on the US Federal Reserve's latest interest rate decision.
Read more(Sharecast News) - Stocks in London look primed for a lower start as investors digest the gains made by far right parties in Austria, Germany, but above all France, at the European Union elections that were held at the weekend.
Read more(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:
Read more(Alliance News) - AstraZeneca PLC on Wednesday said it successfully completed the acquisition of Boston, Massachusetts-based Fusion Pharmaceuticals Inc.
Read more
Last checked at